AhR and Pulmonary Hypertension: A Potential Therapeutic Target

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that regulates gene expression in response to environmental toxins, such as dioxins, polycyclic aromatic hydrocarbons (PAHs), and other xenobiotics. AhR has been implicated in various biological processes, including immune system function, cell proliferation, and differentiation.

Pulmonary hypertension (PH) is a progressive disease characterized by increased pulmonary vascular resistance, leading to right ventricular hypertrophy and heart failure. Several studies have suggested a potential role for AhR in the pathogenesis of PH.

Recent studies have shown that AhR activation by environmental toxins, such as PAHs, can contribute to the development of PH by promoting pulmonary arterial smooth muscle cell proliferation and migration. Additionally, AhR activation can increase endothelial cell dysfunction and inflammation, leading to the development of pulmonary vascular remodeling.

Furthermore, AhR has been shown to regulate the expression of several genes involved in PH pathogenesis, including vascular endothelial growth factor (VEGF), endothelin-1 (ET-1), and nitric oxide synthase (NOS). AhR activation can increase the production of ET-1, a potent vasoconstrictor, and decrease the production of nitric oxide (NO), a potent vasodilator.

Overall, the available evidence suggests that AhR plays a critical role in the development and progression of PH. Therefore, targeting AhR signaling may represent a promising therapeutic strategy for the treatment of PH.